Journal of Clinical Oncology
Articles in this Issue
NOGA: Neoadjuvant treatment optimization via MRI-guided de-escalation in stage II–III TNBC—A phase 2 study.
TPS654 Background: Pembrolizumab combined with neoadjuvant chemotherapy improves pathological complete response (pCR) rate...
Real-world evidence of the association between primary insomnia and early-onset gastrointestinal cancers.
e23414 Background: Although progress has been made in reducing overall cancer incidence, early-onset cancers have continue...
Real-world patient characteristics, treatment patterns and clinical outcomes in patients diagnosed with extra-pulmonary neuroendocrine carcinoma (epNEC): A non-interventional multimodal database analysis in the US.
e16310 Background: Extra-pulmonary neuroendocrine carcinomas (epNECs) represent a rare and aggressive subset of malignant...
Rethinking clinical follow-up for breast cancer survivorship care: A narrative literature review.
e13797 Background: Breast cancer recurrence rates are declining with improvements in therapies. Earlier detection is facil...
Effect of timely immunizations on infection-related outcomes after CLL-directed treatment.
e19032 Background: Patients with Chronic Lymphocytic Leukemia (CLL) are at a higher risk of developing infections due to d...
Efficacy and safety of transarterial therapy combined with donafenib plus PD-1 inhibitors for unresectable hepatocellular carcinoma: A multicenter retrospective study.
e16171 Background: Triple therapy combining transarterial therapy, tyrosine kinase inhibitors (TKIs), and programmed death...
Final analysis of the investigator-initiated randomized study of anti–PD-L1 durvalumab (durva) with radiation versus chemoradiation (CRT) for intermediate-risk HPV-positive (HPV+) locally advanced oropharyngeal squamous cell carcinoma (LA-OPSCC): Canadian Cancer Trials Group (CCTG) HN.9 (EORTC 1740-HNCG).
6017 Background: Primary immunotherapy (IO) with radiotherapy remains an investigational approach in HPV+ LA-OPSCC. The CC...
Survival and pain treatment de-escalation of concurrent chemoradiotherapy combined with nimotuzumab and analgesics for patients with advanced head and neck cancer: A randomized, controlled clinical study.
e18001 Background: Patients with advanced head and neck cancer (HNC) have a poor prognosis. Pain is a disruptive complicat...
Communication of tumor testing and molecular results to patients and caregivers in glioblastoma: A national survey.
e14041 Background: Tumor testing and molecular characterization are essential for personalized care in glioblastoma (GBM),...
Hallmarks-of-cancer in stage II-III NSCLC treated with chemoradiotherapy (CRT).
e20052 Background: Stage II-III NSCLC adenocarcinoma (ADC) treated with definitive CRT is clinically heterogeneous. Post-C...
APOBEC mutational signatures to predict immune checkpoint inhibitor benefit in TMB-low metastatic NSCLC independent of PD-L1 status.
3130 Background: Most metastatic non-small cell lung cancer (NSCLC) patients are tumor mutational burden (TMB)-low (<10...
Outcomes of pneumococcal disease in patients with B-cell malignancies: A retrospective cohort study.
e23110 Background: Streptococcus pneumoniae disproportionately affects adults with B-cell hematologic malignancies due to...
Survival outcomes between neoadjuvant and adjuvant chemo-immunotherapy in patients with stage II–III NSCLC undergoing surgical resection.
8060 Background: In patients with stage II–III NSCLC, perioperative systemic therapy is recommended; however, the optimal...
Epidemiological trends and burden of gastric cancer mortality in South Asia: A retrospective analysis from 1990 to 2023 with advanced machine learning (ARIMA) forecasting to 2050.
e15656 Background: Gastric cancer remains a major cause of cancer-related mortality in South Asia, with substantial hetero...
Sex-specific trends and outcomes in small cell lung cancer (SCLC) in Spain: Insights from the CLARISSE study (2019–2024).
8092 Background: SCLC is an aggressive malignancy with poor prognosis. Although overall incidence is declining, cases amon...
Prognostic value of circulating tumor DNA in muscle-invasive bladder cancer treated with radical cystectomy: A systematic review and meta-analysis.
e16611 Background: Muscle-invasive bladder cancer (MIBC) is an aggressive disease that carries a high risk of disease recu...
Clinicopathologic features of invasive lobular breast carcinoma in Syria: An epidemiological analysis from the country’s main cancer center in 2025.
e13032 Background: Invasive lobular carcinoma (ILC) is a distinct histological subtype of breast cancer that arises from t...
Early results from the first-in-human phase 1 study of WEE1 inhibitor APR-1051 in patients with advanced solid tumors (ACESOT-1051).
3107 Background: WEE1 tyrosine kinase regulates cell cycle checkpoints (G1-S, G2-M) and DNA damage responses. Inhibiting W...
Pancreatic cancer risk and metastatic outcomes in patients with metabolic dysfunction–associated steatotic liver disease.
e16440 Background: Pancreatic cancer (PC) is a malignancy with poor survival outcomes. Metabolic dysfunction–associated st...
User-centered design of a COPD care pathway embedded in oncology care for patients receiving immune checkpoint inhibitors.
1566 Background: Chronic obstructive pulmonary disease (COPD) is one of the most common comorbidities among patients treat...
Tumor-associated macrophage (TAM) score as an independent predictor of recurrence in residual disease after neoadjuvant chemotherapy and for identification of high-risk patients for adjuvant escalation.
522 Background: Tumor-associated macrophages (TAMs) drive immune evasion and chemotherapy resistance in breast cancer thro...
Real-world second-line treatment patterns and outcomes by platinum sensitivity in extensive-stage small cell lung cancer in the post-immunotherapy era.
8083 Background: Platinum-based chemotherapy (PBC) with checkpoint inhibitor (CPI) is standard first-line (1L) treatment f...
Synthetic lethality–informed neoantigen prioritisation to support mechanism-specific therapeutic strategies across human cancers.
2510 Background: Personalised neoantigen vaccines can elicit strong tumour-specific T cell responses, yet tumours may evad...
GEMINI-NSCLC: Multiomics and single-cell spatial profiling to benchmark, back-translate, and build digital twins of IO response.
8533 Background: Response to first-line standard-of-care (SoC) chemo-immunotherapy (IO) for patients with NSCLC without ta...
National patterns of hospitalization, mortality, and resource utilization in Merkel cell carcinoma in the United States, 2018–2022.
e21574 Background: Merkel cell carcinoma (MCC) is a rare, aggressive cutaneous malignancy with limited contemporary nation...